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(G. Dawson).NSMase2 is associated with the plasma membrane, whereas ASMase is predominantly lysosomal;
both hydrolyze sphingomyelin (SM) to ceramide and phosphocholine. Although SM accumulated
in both ASMase/ and fro/fro (NSMase2/) ﬁbroblasts, the reduction of ceramides was more dra-
matic in fro/fro cells. ASMase mRNA, protein and enzyme activity were substantially elevated in
fro/fro ﬁbroblasts. In contrast, NSMase2 activity was unaffected in ASMase/ ﬁbroblasts. ASMase/
cells showed normal cell cycling whereas fro/fro cells grew slowly, were arrested in G1/G0 and could
be corrected by transfection with the smpd3 gene. This suggests two distinct subcellular pathways
for SM catabolism with distinct functions.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Two sphingomyelinases are major players in the regulation of
sphingomyelin and ceramide levels in the cell and both have been
associated with a range of biological actions from proliferation to
cell death [1–5]. We took advantage of the availability of two ani-
mal models to examine possible evidence for cross regulation of
the lysosomal (ASMase) and non-lysosomal (palmitoylated plasma
membrane NSMase2) forms of the enzyme. The ASMase knockout
mouse generated by Horinouchi et al. [6] shows a progressive neu-
rodegenerative course and death occurs at 8 months of age. Patho-
logical studies revealed cerebella atrophy, loss of Purkinje cells and
foam cells in reticuloendothelial organs typical of a lysosomal lipid
storage disease. Subsequent studies revealed an altered response
to radiation-induced stress but it was concluded that ASMase is
non-essential for enhancing the inﬂammatory signals generated
by cytokines [7]. The fro/fro mouse arose from a spontaneouschemical Societies. Published by E
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pholino) ethanesulfonic acid;
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trics MC4068, University of
and Ave., Chicago, IL 60637,
dawg@midway.uchicago.edudeletion of the Smpd3 gene encoding NSMase2 and displays pro-
found skeletal dysplasia, suggesting that NSMase2 plays a direct
role in osteoblast development and bone formation [8]. A previous
study on experimentally-derived Smpd3/ mice concluded that
the loss of NSMase2 activity led to pituitary hormone deﬁciency
in the central nervous system and triggered a series of events that
led to a reduction in circulating IGF-1, causing the observed skele-
tal dysplasia [9]. In general the two NSMase2/ mouse models
show similar skeletal and growth abnormalities and the phenotype
is totally different from that of a lysosomal storage disease. North-
ern blot analysis revealed widespread expression of ASMase but
that the highest level of expression of smpd3 (NSMase2) was in
brain and bone, with lesser expression in skin, sternum, and tra-
chea and very little in heart, kidney, liver, lung and spleen
[10,11]. Although there are many studies on both SMases, there
have been no investigations on coordination between these two
SMases. Therefore we used ASMase/ and fro/fromouse skin ﬁbro-
blasts as a culture system to study the coordination of these two
enzymes, and their effect on cell proliferation.
2. Materials and methods
2.1. Standards and reagents
Sph, DHSph, a 17-carbon analog of Sph (C17-Sph), S1P, DHS1P,
a 17-carbon analog of S1P (C17-S1P), N-myristoyl (14:0), N-palmi-
toyl (16:0), N-oleoyl (18:1), N-stearoyl (18:0), N-arachidoyl (20:0),lsevier B.V. All rights reserved.
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(Cer)), N-palmitoyl (16:0), N-oleoyl (18:1), N-stearoyl (18:0),
N-arachidoyl (20:4), N-behenoyl (22:0), N-nervonoyl (24:1), and
N-lignoceroyl (24:0), and TopFluor-sphingomyelin(SM) were
obtained from Avanti Polar Lipids (Alabaster, AL). The non-phos-
phorylated lipid standards were dissolved in methanol, whereas
the sphingoid base phosphates were dissolved in methanol con-
taining a trace amount of concentrated HCl and were stored at
20 C. [3H] Palmitic acid (43 Ci/mmol) was purchased from
New England Nuclear (Boston, MA). Silica gel high performance
thin-layer chromatography (HPTLC) plates were obtained from
Whatman (Clifton, NJ, USA) and the protein assay kit was
obtained from Bio-Rad Laboratories (Hercules, CA, USA). Chloro-
form, methanol, and acetic acid used for HPTLC were of ACS grade
and obtained from Fisher Scientiﬁc (Pittsburgh, PA, USA). Hexam-
ethylumbelliferyl (HMU)-phosphorylcholine was purchased from
Moscerdam Substrates (Amsterdam, The Netherlands). RT-PCR
primers for Smpd1, Smpd3 and 18s rRNA were obtained from Inte-
grated DNA Technologies (Coralville, IA, USA). The antibodies for
ASMase and NSMase2 were obtained from Santa Cruz Biotechnol-
ogy, Inc. (Santa Cruz, CA, USA), beta-actin antibody and secondary
antibodies anti-mouse, anti-goat and anti-rabbit were purchased
from Sigma (St. Louis, MO, USA).
2.2. Generation of fro/fro (NSMase2/) and ASMase/ mutant mouse
ﬁbroblast cell lines
fro/fro Mouse has been maintained by breeding heterozygous
(+/fro) mice together. To avoid postnatal lethality associated with
fro maintenance, fro was transferred to C57BL/6 N and C3H/HeN
background by repeated backcrosses (>10) of heterozygous (+/
fro) mice. Resulting congenic strains were maintained by breeding
heterozygous mice together [12]. ASMase knock out mice (C57BL/6
strain) were obtained by propagation of heterozygous breeding
pairs [13]. Mouse skin ﬁbroblasts were isolated from sterilized ears
of newly euthanized 2-week-old postnatal mice. Tissue fragments
were plated in 20% bovine FCS in DMEM containing Gentamycin
and colonies of ﬁbroblasts were trypsinized and sub-cultured.
The Vector pCMV 3X-FLAG (Sigma) was used to transfect Smpd3
in the cultured skin ﬁbroblasts. Stable clones were selected on
the basis of neomycin (G418-sulfate) resistance [11].
2.3. Sphingomyelinase assays
ASMase and NSMase activity was determined with the ﬂuori-
metric substrate hexamethylumbelliferyl (HMU)-phosphorylcho-
line as described previously [11]. Brieﬂy, cells were harvested
and washed with phosphate-buffered saline (PBS); the pellets were
resuspended and lysed in 25 mM Tris–HCl, 150 mM NaCl, and 1%
Triton X-100, pH 7.4. For ASMase activity assay, 50 lg protein
was mixed with the ﬂuorogenic substrate HMU-phosphorylcho-
line, and the incubation was carried out at pH 4.5 in 150 mM so-
dium acetate buffer containing 1 mM EDTA to block any NSMase
activity. NSMase2 assay was carried out at pH 7.4. The reaction
buffer (10 mM MgCl2, 100 mM Tris–HCl, pH7.4 and 0.1% Triton
X-100) included 5 mM fresh DTT to inhibit any ASMase activity.
The HMU released was followed ﬂuorometrically in a 96-well
FLX microplate reader. The enzyme activity was calculated from
the slope of the graph of intrinsic ﬂuorescence plotted against time
and standardized to mg of protein.
2.4. RT-PCR for NSMase2 and ASMase mRNA expression in cells
Total RNA was extracted from cultured ﬁbroblasts using a Qia-
gen total RNA extract kit (Valencia, CA, USA). RT-PCR was executed
with a RT-PCR one step kit (Qiagen) and primer pairs speciﬁc tomouse Smpd1 by using forward: 50-TGGTTCTGGCTCTGTTTGAC
TCCA-30 and backward: 50-TCAGCTGATCTTGGCGAGACTGTT-30;
primer pairs speciﬁc to mouse Smpd3 by using forward: 50-ACAT
CGATTCTCCCACCAACACCT-30 and backward: 50-AATTCGCACAATG
CAGCTGTCCTC-30 and 18s rRNA as control, by using Forward: 50-
CCAGAGCGAAAGCATTTGCCAAGA-30 and backward: 50-AATCAACG
CAAGCTTATGACCCGC-30 primers. Brieﬂy, the reaction mixture
was prepared in PCR tubes according to the kit menu and put into
a Perkin Elmer GeneAMP PCR System 2400 (Perkin Elmer,
Waltham, MA, USA). The programming RT-PCR procedure
consisted of reverse transcription (50 C for 30 min), initial PCR
activation (95 C for 15 min), then 35 cycles of 94 C for 30 s,
59 C for 30 s, and 72 C for 1 min, followed by a ﬁnal extension
at 72 C for 10 min. The annealing temperature varied according
to primer Tm. The RT-PCR ampliﬁed samples were visualized on
1.2% agarose gels using ethidium bromide.
2.5. Western blot analysis
Cell lysates from ﬁbroblast cell cultures were subjected to SDS-
gel electrophoresis. Proteins were transferred to Immobilon-P
membranes (Millipore, Bedford, MA), and Western blotting carried
out with antibodies according to the manufacturer’s instructions.
Positive bands were detected with a chemiluminescence kit from
Fisher Scientiﬁc (Pittsburgh, PA). The Western blot bands were
scanned with a Bio-Rad ChemiDoc XRS (Bio-Rad, Hercules, CA).
2.6. Labeling study with TopFluor-sphingomyelin (SM)
TopFluor-SMwas used at a concentration of 1 mg/mL in ethanol.
It was added to cell cultures to achieve a ﬁnal concentration of
0.6 lg/mL. Typical labeling experiments were carried out in 100-
mm Petri dishes, containing 8 mL of serum-free medium, for 24 h.
Cells (3  106/100 mm plate) were harvested and washed three
times with phosphate-buffered saline, and the pellet was extracted
with methanol (1 mL). Following addition of chloroform (2 mL) and
0.01 N HCl (0.6 mL) the upper phasewas discarded, the lower phase
was evaporated to dryness under nitrogen, and lipids applied to
HPTLC plates prior to quantiﬁcation of sphingolipid ﬂuorescence.
2.7. Analysis of lipid synthesis by HPTLC
Cells were labeled with [3H] palmitate and lipids were extracted
as described previously [12]. Typical labeling experiments were
carried out in 100-mm Petri dishes containing 8 ml of serum-free
medium for 24 h. Cells (3  106/100 mm plate) were harvested
and washed three times with phosphate buffered saline, lipids
were extracted by Chloroform–Methanol–water (2:1:0.6 v/v) par-
tition and samples were subjected to alkaline methanolysis to
remove phosphoglycerides. Lipids were applied to HPTLC plates
(10  10 cm; LHP-K TLC plates, Whatman, Inc) and developed in
chloroform: methanol: glacial acetic acid: water (70: 25: 8.8: 4.5
v/v). Lipids were visualized in iodine vapors then scraped off for
quantiﬁcation. Mouse brain (0.1 g) lipids were extracted by
1.2 ml H2O, 2 ml methanol and 4 ml chloroform, and then sub-
jected to alkaline methanolysis to remove phosphoglycerides. Lip-
ids were applied to HPTLC plates and developed in chloroform:
methanol:glacial acetic acid:water (70:25:8.8:4.5 v/v). Sphingomy-
elin was visualized by charring with 10% CuSO4–8% H2SO4 [14].
2.8. Lipid extraction and sample preparation for lipid quantiﬁcation by
LC/MS/MS and analysis of sphingoid bases, sphingoid base 1-
phosphates and ceramides
Cellular lipids were extracted by a modiﬁed Bligh and Dyer [15]
procedure with the use of 0.1 N HCl for phase separation.C17-S1P
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internal standards and were added during the initial step of lipid
extraction. The extracted lipids were dissolved in methanol/chloro-
form (4:1, v/v), and aliquots were taken to determine the total
phospholipid content as described previously [16]. Samples were
concentrated under a stream of nitrogen, redissolved in methanol,
transferred to autosampler vials, and subjected to consecutive LC/
MS/MS analysis of sphingoid bases, ceramides, and sphingoid base
1-phosphates.
Analyses of sphingolipids were performed by combined LC/MS/
MS using an automated Agilent 1100 series liquid chromatograph
and autosampler (Agilent Technologies, Wilmington, DE) coupled
to an API4000 Q-trap hybrid triple quadrupole linear ion trap mass
spectrometer (Applied Biosystems, Foster City, CA) equipped with
a TurboIonSpray ionization source. Sphingolipids were ionized
via electrospray ionization (ESI) with detection via multiple reac-
tions monitoring (MRM). Analysis of sphingoid bases and the
molecular species of ceramides used ESI in positive ions with
MRM analysis [17]. Standard curves for each of the sphingoid
bases, sphingoid base 1-phosphates and ceramides molecular spe-
cies were constructed by adding increasing concentrations of the
individual analyte to 30 or 40 pmol of the corresponding structural
analogs used as the internal standard. Linearity and the correlation
coefﬁcients of the standard curves were obtained by a linear
regression analysis. The standard curves were linear over the range
of 0.0–300 pmol of each of the sphingolipid analytes with correla-
tion coefﬁcients (R2) > 0.98.Fig. 1. Increased activity and expression of ASMase in fro/fro ﬁbroblast. (A) NSMase2 activ
is depleted in fro/fromouse ﬁbroblasts. (C) Increased activity of ASMase in fro/fro mouse
out mouse ﬁbroblasts. (E) NSMase2 activity is unchanged in the ASMase knock out mous
activity of ASMase. SMase activity was determined by ﬂuorometic assay, the procedure
experiments.2.9. Gene expression proﬁling
RNA was extracted from ﬁbroblasts with the Trizol and Qiagen
kit, and RNA integrity was assessed with an Agilent 2100 Bioana-
lyzer (Agilent, Palo Alto, CA). High-quality RNA (RNA integrity
number > 9.0) was used for expression microarray analysis in
which 2 lg of the total RNA was processed for biotin labeled target
preparation and hybridization to affymetrix mouse genome 430
2.0 Genechip expression arrays according to the Genechip Expres-
sion analysis technical manual (Affymetrix, Inc). After hybridiza-
tion for 16 h at 45 C with rotating at 60rpm, arrays were
washed and stained on a GeneChip Fluidics Station (Affymetrix,
Inc.) and scanned using the Gene Chip Scanner 3000 7G. The CEL
intensity data extracted by GCOS (Gene Chip Operating Software)
were used for data analysis. Functional analysis of statistically sig-
niﬁcant gene expression changes was performed with Ingenuity
Pathways Analysis (IPA, Ingenuity Systems) and DNA-Chip Ana-
lyzer (dChip) software (www.dchip.org).
2.10. Flow cytometric analysis of cell cycle
DNA content analysis was performed on cell samples using pre-
viously established ﬂow cytometric methods [18]. Brieﬂy, cells
grown in 6 cm Petri dishes were detached by using Trypsin/EDTA
for 3 min at 37 C, and then washed with PBS with 1% BSA to
achieve a single cell suspension. Cells were centrifuged at 200g
for 5 min, and then resuspended in 1 ml ice-cold 70% ethanol fority is minor compared to ASMase activity in mouse ﬁbroblasts. (B) NSMase2 activity
ﬁbroblasts compared to its control. (D) ASMase activity is depleted in ASMase knock
e compared to its control. (F) Transfection of Smpd3 into fro/fro ﬁbroblast decreases
s are as described in the text and results are representative of three independent
Fig. 2. Increased expression of ASMase in fro/fro ﬁbroblast. (A) RT-PCR showing increased expression of Smpd1 in fro/fro ﬁbroblasts compared to controls. (B) RT-PCR showing
the same expression of Smpd3 in ASMase/ ﬁbroblasts compared to controls. (C) Western blot showing that the increased ASMase expression in fro/fro ﬁbroblast can be
reversed by transfection of smpd3. Bar graphs show quantiﬁcation corrected for RNA and protein, the procedures are as described in the text and results are representative of
three independent experiments.
Table 1
Affymetrix gene chip analysis showing increased expression of Smpd1 in fro/fro cells.
Microarray (affymetric Genechip Data)
WT fro/fro fro/smpd3
smpd3 NM_021494 407 437 414
smpd1 NM_011421 413 1030 893
J. Qin, G. Dawson / FEBS Letters 586 (2012) 4002–4009 40051 h at 4 C. Ethanol-ﬁxed cells were spun at 200g for 7 min and
then washed in PBS once. The washed pellet was stained with
1 ml of a PI staining solution (0.02 mg Propidium Iodide (PI),
0.2 mg RNase A, and 0.1% Triton-X-100 in 1 ml PBS) for 30 min at
room temperature. Cells were immediately analyzed on a
BectonDickinson LSRII analyzer (San Jose, CA) using a 561 nm
excitation source and a 630/30 nm emission ﬁlter. Linear Area
and Width PI ﬂuorescence data was collected as well as Forward
Scatter (FSC) and Side Scatter (SSC) parameters. 10000 single cells
were collected for analysis using FlowJo analysis software
(Treestar, Ashland, OR). Single cells were gated using PI-Width
and Area parameters as well as FSC and SSC gates. DNA content
measurements were calculated using FlowJo’s cell cycle platform
and the Watson (Pragmatic) model. Percent of cells in G1, S-phase,
and G2 was recorded for each sample.
2.11. Statistical analysis
The results of LC–MS/MS analyses are from duplicate experi-
ments run in triplicate. Statistical analyses were performed by Stu-
dent’s t-test, and results were considered statistically signiﬁcant
when p < 0.05.3. Results
3.1. ASMase is increased in fro/fro ﬁbroblasts
We measured both NSMase2 and ASMase activities in ﬁbro-
blasts and found NSMase2 activity to be less than ASMase activity
under optimum assay conditions (Fig. 1A), NSMase2 activities in
fro/fro and ASMase in ASM/ ﬁbroblasts were depleted as ex-
pected (Fig. 1B and 1D). We also found that ASMase activity was
increased in fro/fro ﬁbroblasts. An in vitro assay showed a 7-fold
increase compared to control (Fig. 1C), whereas NSMase2 activity
was not signiﬁcantly changed in ASMase/ ﬁbroblasts (Fig. 1E).
Transfection of Smpd3 into fro/fro ﬁbroblasts decreased the activity
of ASMase to control levels (Fig. 1F). RT-PCR and Western blot
revealed increased expression of Smpd1 and ASMase in fro/fro
ﬁbroblasts, and transfection of Smpd3 into fro/fro ﬁbroblasts
decreased the expression of ASMase (Fig. 2A and 2C). In contrast,
there was no change in expression of Smpd3 in ASMase/
ﬁbroblasts (Fig. 2B). Gene chip expression assay supported the
ﬁndings (Table 1).
3.2. Regulation of sphingomyelin levels by NSMase2 and ASMase
Labeling of cells with [3H] palmitate showed accumulation of
SM in both fro/fro and ASMase/ ﬁbroblasts (Fig. 3A and B). How-
ever, LC/MS/MS analysis revealed that ceramide levels were about
50% in fro/fro ﬁbroblasts (Fig. 3C) compared to its control, but were
less affected in ASMase/ ﬁbroblasts (Fig. 3D). Although the
expression of ASMase in terms of mRNA, protein levels and enzyme
activity was increased in fro/fro ﬁbroblasts, it did not compensate
for the lack of NSMase2. The increased SM and decreased
ceramides, suggested that the lysosomal localization of ASMase
4006 J. Qin, G. Dawson / FEBS Letters 586 (2012) 4002–4009isolated it from the main ceramide-generating systems in fro/fro
ﬁbroblasts. LC/MS/MS analysis revealed that ceramides were re-
duced across the board in terms of fatty acid content and levels
(Fig. 3C and D). Since S1P is derived from ceramides through sphin-
gosine, we also measured sphingoid bases and found a substantial
reduction of S1P (reduced to 75% of control levels) in fro/fro ﬁbro-Fig. 3. Sphingomyelin and ceramide analysis in fro/fro and ASMase/ mouse skin ﬁb
palmitate-labeled sphingolipids showing increased SM in fro/fro ﬁbroblasts. Quantiﬁcatio
of Smpd3 into fro/fro ﬁbroblasts decreases the accumulation of SM. (B) Autoradiogram
sphingolipids showing increased SM in ASMase/ ﬁbroblasts. Quantiﬁcation showed >2
shows that the amount of all ceramide species was signiﬁcant decreased in fro/fro compar
amount of all ceramide species is less decreased in ASMase/ compared to normal (W
ceramides in mouse ﬁbroblasts. (E and F) Recovered activity of NSMase2 and total cerami
in the text and results are representative of three independent experiments.blasts (data not shown). Transfection of the fro/fro ﬁbroblasts with
Smpd3 restored the NSMase2 activity and reduced ceramide levels
to normal (Fig. 3E and F). LC/MS/MS analysis also showed that in
ﬁbroblasts the C16:0, C24:0 and C24:1-ceramide molecular species
were the major ceramides compared to C18:0-ceramide in brain
[19]. Thus the ﬁbroblast-brain differences may be explained byroblasts. (A) Autoradiogram of HPTLC of samples of normal (WT) and fro/fro [3H]
n of autoradiogram showed a >3 increase of SM in fro/fro ﬁbroblasts. Transfection
of HPTLC of samples of normal (WT) and NPD (ASM/) [3H] palmitate-labeled
 increase of SM in ASMase/ ﬁbroblasts. (C) Ceramide analysis by HPLC/MS/MS
ed to normal (WT) ﬁbroblasts. (D) Ceramide analysis by HPLC/MS/MS shows that the
T) ﬁbroblasts. C16:0, C24:0 and C24:1-ceramide molecular species were the major
des by transfection of Smpd3 into fro/fro ﬁbroblasts. The procedures are as described
Fig. 4. SM accumulates and ceramides decrease in both fro/fro and ASMase/
ﬁbroblasts following loading with TopFluor-SM and HPTLC analysis. TopFluor-SM
labeling of cells led to SM accumulation and ceramide decreases in both fro/fro and
ASMase/ ﬁbroblasts compared to their controls but the effect was greater in the
ASMase/ cells. The procedures are as described in the text and results are
representative of three independent experiments.
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analysis of fro/fro brain and calvaria revealed a 50% reduction in
ceramide [11], whereas no differences in ceramides were found
in ASMase/ brain.
3.3. ASMase cannot completely compensate for NSMase2 (and vice
versa) in their respective knockout mouse ﬁbroblasts
TopFluor-SM labeling experiments showed that SM accumu-
lated and ceramides decreased in both fro/fro and ASMase/ ﬁbro-
blasts. The effect was less (a 75% reduction) in fro/fro cells (Lane 2)Fig. 5. Cell cycle abnormalities occur in fro/fro ﬁbroblasts. (A) Cell cycle analysis of WT a
described in the text. (B) Cell cycle analysis of WT and ASMase/ ﬁbroblasts showed no d
of three independent experiments.compared to 90% in ASMase/ cells (lane 4) but clearly shows that
ASMase and NSMase2 cannot compensate for each other (Fig. 4).
3.4. NSMase2 and the cell cycle
The fro/fro mice showed slow growth which was mimicked in
ﬁbroblasts but was not seen in ASMase/ ﬁbroblasts. Cell cycle
analysis by FACS showed initially that very few (only 8% compared
to 42% in controls) of the fro/fro ﬁbroblasts were in S-phase
whereas 83% of cells were in G1 phase compared to only 40% in
control cells (Fig. 5A). This could explain why they grew slowly,
had aberrant morphology and were mostly arrested in G1/Go. Cells
in S-phase were increased to 35% following transfection with
Smpd3 (Fig. 5A). ASMase/ ﬁbroblasts grew normally and were
morphologically normal (Fig. 5B).
4. Discussion
The accumulation of SM in ASMase/ cultured cells has been
previously well documented but less attention has been paid to
the role of NSMase2. NSMase 2 is one of the major intracellular
regulators of ceramide levels and hydrolyzes non-lysosomal SM
to ceramide but always appears to be the minor SMase by
in vitro assay. However, our analysis shows that NSMase2 is in-
volved in cell growth unlike ASMase, which could be ascribed to
their working in different subcellular compartments. We now
present data to support this idea. We have previously shown that
stress (e.g. Staurosporine or C2-ceramide) induces the transloca-
tion of NSMase2 into lipid rafts [21], and this is supported by evi-
dence that NSMase2 is dynamically palmitoylated [22]. The fro/fro
mouse (with a deletion of the part of the Smpd3 gene coding for
the active site of NSMase2) has major deﬁcits in growth and
development [8,9]. In contrast, the absence of ASMase did not af-
fect growth rates or the cell cycle. NSMase2 absence (but not lyso-
somal ASMase absence) resulted in a 50% reduction in all
ceramides [11], although the accumulation of SM was signiﬁcant
in both ASMase/ and in fro/fro ﬁbroblasts. Neither NSMase2
nor ASMase showed substrate speciﬁcity for a particular ceramide
species (based on LC/MS/MS assay), unlike the situation withnd fro/fro ﬁbroblasts and the correction with Smpd3 transfection was carried out as
ifferences. The procedures are as described in the text and results are representative
4008 J. Qin, G. Dawson / FEBS Letters 586 (2012) 4002–4009ceramide synthases [20]. NSMase2 has optimal activity at pH 7.4
and requires divalent cations such as Mg2+ or Mn2+. In contrast,
ASMase has a pH optimum at pH 4.5 and is phosphate sensitive,
thus ASMase and NSMase2 function in different cell compart-
ments. ASMase undergoes an especially complex post-translation
proteolytic processing [23,24] and recent reports suggest that
some ASMase could be active at the cell surface [25–27]. In addi-
tion, Aureli et al. reported that there were different patterns of
SM-protein complexes in lipid rafts prepared from normal and
Nieman-Pick types A disease (NPA) ﬁbroblasts, suggesting that
differences in lipid and protein compositions of cell lines deter-
mine speciﬁc lipid-protein interactions and different clustering
within plasma membrane [28]. NSMase2 is activated by proteins
such as FAN, and caspase 8 as well as divalent cations such as
Mg2+ and Mn2+ and glutathione [29]. In contrast, required activa-
tors of ASMase include members of the Saposin family of lyso-
somal hydrolyase activator proteins as well as certain heat
shock proteins (e.g. hsp70) [30]. NSMase2 inhibitors include
GW4869, whereas ASMase inhibitors include desipramine and
FTY720 [31] and there is no overlap in the inhibitors.
We were surprised that the absence of NSMase2 resulted in a
dramatic increase in ASMase although this did not functionally
translate into a compensatory reduction of SM or an increase in
ceramides back to normal levels. One possible reason is that in
fro/fro, SM accumulates in plasma membrane because of the lack
of NSMase2 activity, leading to more SM being delivered to lyso-
somes through endocytic vesicles and thereby stimulating more
ASMase expression. In contrast, the accumulated SM in lysosomes
in ASMase/ ﬁbroblasts cannot be recycled to the PM, and there-
fore no synthesis of NSMase2 is stimulated. We have presented
evidence based on [3H] palmitate labeling and HPTLC analysis that
the lack of NSMase2 results in both SM accumulation and ceramide
depletion in cultured ﬁbroblasts and this can be corrected by trans-
fection of Smpd3 gene. In contrast, although SM also accumulates
in ASMase/ cells, the depletion of ceramide was less obvious.
This difference (the relative lack of ceramide accumulation in ASM-
ase/ cells) was previously shown by analysis of brain lipids in the
two mouse models [11]. Although the TopFluor-SM loading exper-
iment shows that ASMase and NSMase2 activity cannot compen-
sate for the lack of the other, and ceramides were depleted in
both types of knock out cells, the LC/MS/MS analysis showed that
ceramide levels in ASMase/ ﬁbroblasts were little decreased. This
suggests that either the ceramide de novo pathway or the ceramide
synthase pathway is activated in ASMase/ ﬁbroblasts but not in
fro/fro ﬁbroblasts. This needs to be further investigated because of
the importance of SM and ceramides in many cellular and patho-
logical processes.
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